Work

Phase II trial of ixazomib combined with gemcitabine and doxorubicin in patients with SMARCB1-deficient kidney malignancies.

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.7_suppl.tps678

Authors: Pavlos Msaouel, Rebecca Slack-Tidwell, Giannicola Genovese, Najat C. Daw, Arlene O. Siefker-Radtke, Nizar M. Tannir

Institution: The University of Texas MD Anderson Cancer Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2921576178

Cites:

Cited by: 7

Related to: 10